New Publication: Activities of daily living in myotonic dystrophy type 1

Our new paper on activities of daily living in patients with myotonic dystrophy type 1 (DM1) is now available online at Acta Neurologica Scandinavica. We were pleased to work with collaborators from Stockholm, Newcastle, London, Glasgow, Maastricht, and Freiburg on this project, which formed part of the PhenoDM1 study (NCT02831504) and included data from 192 individuals with DM1.

The recent development of potential therapies for DM1 has resulted in a need to map out the natural history of the disease to aid the design of clinical trial programs. Using a previously designed scale for self-reporting of daily living activities (DM1-Activc) we showed that patients struggled most with more challenging activities such as running, standing on one leg and carrying heavy objects and that the overall DM1-Activc score decreased with increased disease duration; however, most patients were still able to perform activities of daily living, like grooming and showering, throughout the course of their disease. In addition, the progenitor CTG repeat length in the patient cohort correlated with DM1-Activc scores, adding to the evidence suggesting that repeat length is the most important determinant of the biology of the disease.

Activities of daily living in myotonic dystrophy type 1.
Landfeldt E, Nikolenko N, Jimenez-Moreno C, Cumming S, Monckton DG, Faber CG, Merkies ISJ, Gorman G, Turner C, Lochmüller H.
Acta Neurol Scand. 2019 Dec 30. doi: 10.1111/ane.13215.
PMID: 31889295

Abstract

Objectives
The objective of this cross‐sectional, observational study was to investigate performance of activities of daily living in patients with myotonic dystrophy type 1 (DM1).

Materials & Methods
Adults with genetically confirmed DM1 were recruited from Newcastle University (Newcastle upon Tyne, UK) and University College London Hospitals NHS Foundation Trust (London, UK). Data on activities of daily living was recorded through the DM1‐ActivC (scale scores range between 0 and 100, where a higher/lower score indicates a higher/lower ability).

Results
Our sample comprised 192 patients with DM1 (mean age: 46 years; 51% female). Patients reported most difficulties with running, carrying and putting down heavy objects, and standing on one leg, and least difficulties with eating soup, washing upper body, and taking a shower. Irrespective of the disease duration (mean: 20 years), most patients were able to perform basic and instrumental activities of daily living (e.g., personal hygiene and grooming, showering, eating, cleaning, and shopping), with the exception of functional mobility/transfer tasks (e.g., walking uphill and running). The mean DM1‐ActivC total score was estimated at 71 (95% CI: 68–74). Estimated progenitor cytosine‐thymine‐guanine repeat length and age explained 27% of the variance in DM1‐ActivC total scores (p < 0.001).

Conclusions
We show that DM1 impairs performance of activities of daily living, in particular those requiring a high degree of muscle strength, stability, and coordination. Yet, across the evolution of the disease, the majority of patients will still be able to independently perform most basic and instrumental activities of daily living.

The article can be found here.

Picture1

Read next...

We are hiring a new clinical research coordinator!

Lochmüller Research Group Hiring Clinical Trial Coordinator

Due to recent funding success and expansion of our clinical trials team we have a need for a highly motivated Research Coordinator that will assist...
First participant screened in global CMS natural history study

The Ottawa Neuromuscular Centre screens first participant in the world for a multinational congenital myasthenic syndrome natural history study

The neuromuscular centre at The Ottawa Hospital is excited to announce that we are the first site globally to screen a participant for the multinational...
Copy of Lochmuller Lab - PhD opportunity (LLab)

Lochmüller Lab seeking PhD student

The Lochmüller Research Group are seeking a highly motivated PhD student to join our team at the Childrens Hospital of Eastern Ontario Research Institute (CHEO...
New Publication - Leading global expert in DMD and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for biphosphonate therapy in glucocorticoid-treated patients with Duchenne Muscular Dystrophy in Neurology, with Dr. Hanns Lochmüller as a co-author.

New Publication: Bisphosphonates in Glucocorticoid-Treated Patients with Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence

Leading global expert in Duchenne Muscular Dystrophy (DMD) and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for bisphosphonate therapy in...
text reding new clinical trial opportunities

New Clinical Trial Opportunities for Children and Adults in Ottawa

Our clinical research team is excited to share five new clinical trials activated across both pediatric and adult sites in Ottawa, CHEO and TOH. We...
Dr. Andreas Roos receiving award on WMS 2023 stage, with text reading Congratulaions Dr. Andreas Roos, WMS President's Prize for Emerging Myologist of the Year 2023.

Dr. Andreas Roos wins Emerging Myologist of the Year Prize at WMS 2023

We are excited to congratulate Dr. Andreas Roos on winning the World Muscle Society’s (WMS) President’s Prize for Emerging Myologist of the Year!   This award...